Tirzepatide Once Weekly for the Treatment of Obesity: Participants in this study complete a 60-week Weight-Loss Period on Tirzepatide, followed by a 52-week Weight Maintenance Period, where they are assigned to either Tirzepatide 5 mg, the maximum tolerated dose of Tirzepatide, and saw successful results
BPC 157 and Standard Angiogenic Growth Factors Key Findings: BPC-157, when compared to standard peptidergic angiogenic growth factors (EGF, FGF, VEGF), has been effective in all models of acute/chronic injury of the gastrointestinal tract, whether administered intraperitoneally, per-orally, or locally
That size cutoff is the entire pharmacological bet, because small peptides are the part of a neurotrophic signal that might actually cross the blood-brain barrier, the gatekeeping wall that blocks the bodys own large growth factors from reaching the brain from the bloodstream
For mechanism differences between the two compounds, start with our CJC-1295 vs Ipamorelin research comparison